Mustang Bio gets Nasdaq reprieve. Mustang Bio stock needs USD 1.00 bids

Published on 10/16/2026 at 05:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Mustang Bio received a second 180-day Nasdaq grace period on October 15, 2026. Mustang Bio stock needs USD 1.00 bids.

Compliance and quarterly metrics

Mustang Bio received a second 180-day Nasdaq grace period on October 15, 2026, tied to the USD 1.00 bid rule.
Second-quarter 2026 net loss reached USD 1.072 million, while cash stood at USD 15.2 million.
Mustang Bio is expected to report its next quarterly results on November 18, 2026.

MBIO, US62818Q3020, Illustration mit AI erstellt.

Mustang Bio, Inc. (ISIN US62818Q3020) received a second 180-day Nasdaq grace period on October 15, 2026, to regain compliance with the USD 1.00 minimum bid requirement. TradingView reported that the deadline now runs until April 12, 2027.

Nasdaq sets a 10-day test

The company had spent its initial 180-day cure period, which ended October 12, 2026, after its stock closed below USD 1.00 for 30 consecutive business days. The new period requires a closing bid of at least USD 1.00 for 10 consecutive business days, according to TradingView.

The company told Nasdaq that it may use a reverse stock split if necessary, but the filing summary said compliance is not assured. That condition makes the April 12, 2027 deadline more than a calendar marker: it is the next formal test for MBIO's continued Nasdaq listing.

What do the latest results show?

Mustang Bio reported a USD 1.072 million net loss in the second quarter of 2026, compared with a USD 955,000 loss in the first quarter. Cash declined from USD 16.258 million on March 31, 2026, to USD 15.150 million on June 30, 2026, while operating cash flow was negative USD 967,000 in the second quarter. These figures appear in the Q2 2026 financial summary from ToAlpha.

The latest quarterly loss was also reported as adjusted earnings per share of negative USD 0.16 for the second quarter of 2026. Mustang Bio describes itself as a clinical-stage biopharmaceutical company developing cell and gene therapies for difficult-to-treat cancers, including CAR-T programs, according to its company investor-relations page.

Key dates for MBIO

On April 15, 2026, Mustang Bio received its initial Nasdaq minimum-bid notice after 30 consecutive business days below USD 1.00, as TradingView reported. On October 12, 2026, the first cure period ended. On October 15, 2026, Nasdaq granted the additional 180-day period.

Upcoming reporting date

Mustang Bio is expected to publish its next quarterly results on November 18, 2026, according to TradingView. The report will give investors a fresh reference point for cash use, losses and the company's progress during the extended Nasdaq compliance period.

Listing risk remains the key variable

Mustang Bio's common stock trades on Nasdaq under the ticker MBIO, and the company operates in the healthcare biotechnology industry, according to Investing.com. The listing test and the second-quarter cash position now define the clearest near-term milestones for the stock.